Amgen Agrees to Pay $762 Million in Drug Marketing Case
The company pleaded guilty to misbranding its anemia drug Aranesp, meaning selling it for uses not approved by the F.D.A.
Source: http://goo.gl/mag/CmCkgdH
Amgen Agrees to Pay $762 Million in Drug Marketing Case
The company pleaded guilty to misbranding its anemia drug Aranesp, meaning selling it for uses not approved by the F.D.A.
Source: http://goo.gl/mag/CmCkgdH
No comments:
Post a Comment